Oculus Innovative Sciences' Partner, More Pharma, Launches Microcyn(R)-Based Oral and Throat Infection Treatment Product in

Oculus Innovative Sciences' Partner, More Pharma, Launches Microcyn(R)-Based
Oral and Throat Infection Treatment Product in Mexico

PETALUMA, Calif., April 22, 2014 (GLOBE NEWSWIRE) -- Oculus Innovative
Sciences, Inc. (Nasdaq:OCLS) a global healthcare company that designs,
manufactures and markets prescription and non-prescription products in 33
countries, today announced the commercialization in Mexico of the first
product under the Microdacyn60® Oral Care brand intended for use as an adjunct
treatment in both mouth and throat infections.Commercialized under the brand
name Microdacyn60™ Bucofaringeo™, it is now available in Mexican
pharmacies.At the same time, the More Pharma sales team is introducing the
treatment to general practitioners along with ear, nose and throat specialists
throughout Mexico.

Guillermo Ibarra, More Pharma's CEO said, "With global concerns about the
overuse and misuse of antibiotics in the treatment of pathogen-related
infections, a safe and effective oral antiseptic such as Microdacyn60
Bucofaringeo™, which doesn't facilitate antibiotic resistance, is being well
received by the Mexican healthcare community. In addition to Mexico, we are
proactively assessing the opportunities for Microdacyn60 Bucofaringeo™ in
other Latin American countries."

More Pharma intends to educate Mexican healthcare professionals on the
benefits of Microdacyn60 Bucofaringeo™ while making it widely available in
advance of the 2014 fall/winter cold and flu season.

Bruce Thornton, executive vice president of Oculus said: "Our Latin American
partner, More Pharma, has certainly been fleet of foot in terms of moving this
new oral and throat infection treatment from regulatory approval, just a few
short months ago, into multiple distribution channels and pharmacies
throughout Mexico today."

About More Pharma

Founded in 2007, More Pharma is a pharmaceutical company with strong growth
performance and a team of more than 300 people. The company has a talented
sales and marketing team with significant prior experience with large
international pharmaceutical companies.They have ample funding and support by
their renowned financial sponsors, Southern Cross Group and Evercore, both of
which manage more than $1 billion of venture funds.The company is dedicated
to finding solutions to healthcare challenges via product development,
in-licensing and product acquisitions.With headquarters in Mexico City, More
Pharma has a presence in Mexico, Latin America and the Caribbean.More
information can be found at www.morepharmacorp.com/eng/index.php.

About Oculus Innovative Sciences

Oculus Innovative Science is a global healthcare company that designs,
manufactures and marketsprescription and non-prescription products in 33
countries. The company's products are used to treat patients in
surgical/advanced wound management, dermatology, women's health and animal
health; addressing the unmet medical needs of these markets—while raising the
standard ofpatient care and lowering overall healthcare costs.The company's
headquarters are in Petaluma, California, with manufacturing operations in the
United States and Latin America. More information can be found

Forward-Looking Statements

Except for historical information herein,matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the Company's commercial and technology progress and futurefinancial
performance. These forward-looking statements are identified by the use of
words such as "growth," "expansion" and"build,"among others. Forward-looking
statements in this press release are subject to certain risks and
uncertainties inherent in the Company's business that could cause actual
results to vary, includingsuchrisks thatregulatory clinical and guideline
developments may change,scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or
approvals,clinical results may not be replicated in actual patient
settings,protection offered bythe Company'spatents and patent applications
may be challenged, invalidated or circumvented by its competitors,the
available market fortheCompany'sproducts will not be as large as
expected,the Company'sproducts will not be able to penetrate one or more
targeted markets,revenues will not be sufficient to fund further development
and clinical studies, the Company may not meet itsfuture capital needs, and
its ability to obtain additional funding, as well as uncertainties relative to
varying product formulations and a multitude of diverse regulatory and
marketing requirements in different countries and municipalities, and other
risks detailed from time to time in the Company's filings with the Securities
and Exchange Commission including the annual report on Form 10-K for theyear
ended March 31, 2013. Oculus Innovative Sciences disclaims any obligation to
update these forward-looking statements except as required by law.

Oculus and Microcyn Technology are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service marks are
the property of their respective owners.

CONTACT: Media and Investor Contact:
         Oculus Innovative Sciences, Inc.
         Dan McFadden
         VP of Public and Investor Relations
         (425) 753-2105
Press spacebar to pause and continue. Press esc to stop.